Hyperthermic Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Summary
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC) at the time of surgery may be considered medically necessary for pseudomyxoma peritonei and diffuse malignant peritoneal mesothelioma. For newly diagnosed epithelial ovarian or fallopian tube cancer, HIPEC at interval cytoreductive surgery may be considered medically necessary only when all listed criteria are met: stage III disease, ineligibility for primary cytoreductive surgery (or incomplete surgery followed by neoadjuvant chemotherapy and interval debulking surgery), and expected complete or optimal cytoreduction. HIPEC in all other ovarian cancer settings, including stage IIIC or IV, cytoreductive surgery plus HIPEC for peritoneal carcinomatosis from colorectal, gastric or endometrial cancer, and all other indications, including goblet cell tumors of the appendix, are considered investigational.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.